{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:48:44Z","timestamp":1784731724952,"version":"3.55.0"},"reference-count":233,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21\\u20131\\u20130267"],"award-info":[{"award-number":["W81XWH-21\\u20131\\u20130267"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19\\u20131\\u20130777"],"award-info":[{"award-number":["W81XWH-19\\u20131\\u20130777"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA156734"],"award-info":[{"award-number":["U54CA156734"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA282906"],"award-info":[{"award-number":["R01CA282906"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA299202"],"award-info":[{"award-number":["R01CA299202"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012005","name":"University of Massachusetts Boston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jncc.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T09:19:31Z","timestamp":1750238371000},"page":"58-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-8801","authenticated-orcid":false,"given":"Shuai","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1817-236X","authenticated-orcid":false,"given":"Nolan D.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-2586","authenticated-orcid":false,"given":"Changmeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0001","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jcb.10653","article-title":"Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence","volume":"91","author":"Taplin","year":"2004","journal-title":"J Cell Biochem"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0002","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"10.1016\/j.jncc.2025.05.003_bib0003","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/onc.2013.235","article-title":"Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis","volume":"33","author":"Yuan","year":"2014","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.jncc.2025.05.003_bib0004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jncc.2025.05.003_bib0005","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0006","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.003_bib0007","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jncc.2025.05.003_bib0008","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0009","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.05.003_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.06.016","article-title":"Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial","volume":"155","author":"Caffo","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"issue":"10398","key":"10.1016\/j.jncc.2025.05.003_bib0013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0014","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.jncc.2025.05.003_bib0015","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0016","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.jncc.2025.05.003_bib0017","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1158\/1078-0432.CCR-23-0731","article-title":"Neoadjuvant Cabazitaxel plus Abiraterone\/leuprolide acetate in patients with high-risk prostate cancer: ACDC-RP Phase II trial","volume":"29","author":"Fleshner","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0018","article-title":"Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: trial results and insights into \"ARness\"","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0019","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of Bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300171","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0021","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","article-title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study","volume":"19","author":"Teply","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0022","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.003_bib0023","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.20.02759","article-title":"TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus Enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.05.003_bib0024","article-title":"Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: a systematic review","volume":"13","author":"You","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"issue":"28","key":"10.1016\/j.jncc.2025.05.003_bib0026","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"6320","key":"10.1016\/j.jncc.2025.05.003_bib0027","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0028","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0029","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","article-title":"The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression","volume":"36","author":"Su","year":"2019","journal-title":"Cancer Cell"},{"issue":"4850","key":"10.1016\/j.jncc.2025.05.003_bib0030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1126\/science.3353726","article-title":"Molecular cloning of human and rat complementary DNA encoding androgen receptors","volume":"240","author":"Chang","year":"1988","journal-title":"Science"},{"issue":"4850","key":"10.1016\/j.jncc.2025.05.003_bib0031","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1126\/science.3353727","article-title":"Cloning of human androgen receptor complementary DNA and localization to the X chromosome","volume":"240","author":"Lubahn","year":"1988","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.003_bib0032","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1210\/mend-5-12-1921","article-title":"The promoter of the prostate-specific antigen gene contains a functional androgen responsive element","volume":"5","author":"Riegman","year":"1991","journal-title":"Mol Endocrinol"},{"issue":"1\u20132","key":"10.1016\/j.jncc.2025.05.003_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mce.2011.09.037","article-title":"Chromatin binding by the androgen receptor in prostate cancer","volume":"360","author":"Itkonen","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0034","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1210\/me.2003-0020","article-title":"The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes","volume":"17","author":"Gao","year":"2003","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cell.2005.05.008","article-title":"Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1","volume":"122","author":"Carroll","year":"2005","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0036","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","article-title":"FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription","volume":"132","author":"Lupien","year":"2008","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0037","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/labinvest.2014.64","article-title":"FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype","volume":"94","author":"DeGraff","year":"2014","journal-title":"Lab Invest"},{"issue":"22","key":"10.1016\/j.jncc.2025.05.003_bib0038","doi-asserted-by":"crossref","first-page":"10421","DOI":"10.1073\/pnas.90.22.10421","article-title":"Hepatocyte nuclear factor 3\/fork head or \"winged helix\" proteins: a family of transcription factors of diverse biologic function","volume":"90","author":"Lai","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0039","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/nar\/23.7.1184","article-title":"Analysis of hepatocyte nuclear factor-3 beta protein domains required for transcriptional activation and nuclear targeting","volume":"23","author":"Qian","year":"1995","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1097-2765(02)00459-8","article-title":"Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4","volume":"9","author":"Cirillo","year":"2002","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molcel.2016.03.001","article-title":"The pioneer transcription factor FoxA maintains an accessible nucleosome configuration at enhancers for tissue-specific gene activation","volume":"62","author":"Iwafuchi-Doi","year":"2016","journal-title":"Mol Cell"},{"issue":"7406","key":"10.1016\/j.jncc.2025.05.003_bib0042","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0043","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0044","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.jncc.2025.05.003_bib0045","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.jncc.2025.05.003_bib0046","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","article-title":"Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.05.003_bib0047","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0048","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.jncc.2025.05.003_bib0049","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1073\/pnas.0500381102","article-title":"Structural basis for antagonism and resistance of bicalutamide in prostate cancer","volume":"102","author":"Bohl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jncc.2025.05.003_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13059-015-0864-1","article-title":"Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients","volume":"17","author":"Lallous","year":"2016","journal-title":"Genome Biol"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0051","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ijc.32242","article-title":"Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models","volume":"145","author":"Sugawara","year":"2019","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0052","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0053","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The effect of F877L and T878A mutations on androgen receptor response to enzalutamide","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0054","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Zhao","year":"2000","journal-title":"Nat Med"},{"issue":"Pt 4","key":"10.1016\/j.jncc.2025.05.003_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1107\/S2053230X23002224","article-title":"A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations","volume":"79","author":"Doamekpor","year":"2023","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0056","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0057","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0058","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.jncc.2025.05.003_bib0059","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.003_bib0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0061","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.18632\/oncotarget.14296","article-title":"A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0062","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.jncc.2025.05.003_bib0063","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","article-title":"Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens","volume":"69","author":"Waltering","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.05.003_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021845","article-title":"Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2","volume":"12","author":"Labaf","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0066","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1038\/s41467-024-52032-y","article-title":"Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells","volume":"15","author":"Safi","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0067","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","article-title":"Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1","volume":"20","author":"Cai","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0068","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/0008-5472.CAN-07-6017","article-title":"Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex","volume":"68","author":"Wang","year":"2008","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0069","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1093\/nar\/gkq084","article-title":"Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer","volume":"38","author":"Zhou","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EC-19-0340","article-title":"AR mRNA stability is increased with AR-antagonist resistance via 3\u2032UTR variants","volume":"9","author":"Dart","year":"2020","journal-title":"Endocr Connect"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0071","first-page":"314","article-title":"Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0072","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"Cancer genome atlas research N. The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0073","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0074","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0075","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.jncc.2025.05.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178604","article-title":"Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer","volume":"134","author":"Zhu","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0077","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0078","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Sun","year":"2010","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0079","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.jncc.2025.05.003_bib0080","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","article-title":"Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance","volume":"23","author":"Kohli","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"39","key":"10.1016\/j.jncc.2025.05.003_bib0081","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0082","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1210\/en.2007-0446","article-title":"A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions","volume":"148","author":"Jagla","year":"2007","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0083","first-page":"74","article-title":"Androgen receptor function is modulated by the tissue-specific AR45 variant","volume":"272","author":"Ahrens-Fath","year":"2005","journal-title":"FEBS J"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0084","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-11-0141","article-title":"Alternatively spliced androgen receptor variants","volume":"18","author":"Dehm","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0085","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.jncc.2025.05.003_bib0086","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/onc.2013.284","article-title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0087","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1158\/1078-0432.CCR-13-1863","article-title":"Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer","volume":"20","author":"Yu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0088","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1593\/neo.13784","article-title":"AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer","volume":"15","author":"Liu","year":"2013","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0089","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0090","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0091","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molcel.2018.08.029","article-title":"ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer","volume":"72","author":"Cai","year":"2018","journal-title":"Mol Cell"},{"issue":"26","key":"10.1016\/j.jncc.2025.05.003_bib0092","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0093","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/nar\/gkx1306","article-title":"Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer","volume":"46","author":"He","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0094","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"ARv7 Represses tumor-suppressor genes in castration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0096","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.jncc.2025.05.003_bib0097","doi-asserted-by":"crossref","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","article-title":"Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal","volume":"287","author":"Chan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jncc.2025.05.003_bib0098","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73396","article-title":"AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer","volume":"11","author":"Kim","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.jncc.2025.05.003_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.03.017","article-title":"Reprogramming of androgen receptor activity in castration-resistant prostate cancer is shaped by truncated variants","author":"Lawrence","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"13","key":"10.1016\/j.jncc.2025.05.003_bib0100","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-18-4276","article-title":"Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer","volume":"25","author":"Bernemann","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0101","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1078-0432.CCR-18-0320","article-title":"Expression of AR-V7 and ARv(567es) in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY","volume":"25","author":"Tagawa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0102","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-20-1807","article-title":"JMJD6 Is a druggable oxygenase that regulates AR-V7 expression in prostate cancer","volume":"81","author":"Paschalis","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.05.003_bib0103","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2021.07.013","article-title":"Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells","volume":"519","author":"Liang","year":"2021","journal-title":"Cancer Lett"},{"issue":"17","key":"10.1016\/j.jncc.2025.05.003_bib0104","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115089","article-title":"Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer","volume":"44","author":"Poluben","year":"2025","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0106","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1074\/jbc.M113.492140","article-title":"Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine\/paracrine factors","volume":"289","author":"Sun","year":"2014","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0107","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1073\/pnas.0408925102","article-title":"Mutation of the androgen receptor causes oncogenic transformation of the prostate","volume":"102","author":"Han","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"Hornberg","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0109","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI66666","article-title":"ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer","volume":"123","author":"Cai","year":"2013","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0111","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI78815","article-title":"SOX9 drives WNT pathway activation in prostate cancer","volume":"126","author":"Ma","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0112","first-page":"605","article-title":"Identification of three proline-directed phosphorylation sites in the human androgen receptor","volume":"9","author":"Zhou","year":"1995","journal-title":"Mol Endocrinol"},{"issue":"32","key":"10.1016\/j.jncc.2025.05.003_bib0113","doi-asserted-by":"crossref","first-page":"29304","DOI":"10.1074\/jbc.M204131200","article-title":"Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites","volume":"277","author":"Gioeli","year":"2002","journal-title":"J Biol Chem"},{"issue":"Pt 2","key":"10.1016\/j.jncc.2025.05.003_bib0114","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BJ20040683","article-title":"Phosphorylation of androgen receptor isoforms","volume":"383","author":"Wong","year":"2004","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0115","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1210\/me.2005-0351","article-title":"Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization","volume":"20","author":"Gioeli","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"38","key":"10.1016\/j.jncc.2025.05.003_bib0116","doi-asserted-by":"crossref","first-page":"25576","DOI":"10.1074\/jbc.M109.043133","article-title":"Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1","volume":"284","author":"Chen","year":"2009","journal-title":"J Biol Chem"},{"issue":"24","key":"10.1016\/j.jncc.2025.05.003_bib0117","first-page":"6841","article-title":"HER-2\/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway","volume":"60","author":"Wen","year":"2000","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.jncc.2025.05.003_bib0118","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1073\/pnas.121173298","article-title":"Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor","volume":"98","author":"Lin","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0119","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/MCB.25.4.1298-1308.2005","article-title":"Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor","volume":"25","author":"Yang","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2006.08.021","article-title":"Regulation of androgen receptor activity by tyrosine phosphorylation","volume":"10","author":"Guo","year":"2006","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0121","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/6495","article-title":"A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase","volume":"5","author":"Craft","year":"1999","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0122","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1073\/pnas.1120985109","article-title":"Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression","volume":"109","author":"Drake","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"43","key":"10.1016\/j.jncc.2025.05.003_bib0123","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1073\/pnas.0604193103","article-title":"Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1","volume":"103","author":"Chen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0124","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1074\/jbc.M111.325290","article-title":"Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation","volume":"287","author":"Chen","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jncc.2025.05.003_bib0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2018.09.014","article-title":"Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer","volume":"438","author":"Russo","year":"2018","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0126","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/1878-0261.12968","article-title":"Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer","volume":"15","author":"Gao","year":"2021","journal-title":"Mol Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.003_bib0127","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1210\/me.2010-0238","article-title":"CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation","volume":"24","author":"Gordon","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0128","first-page":"3738","article-title":"Positive feedback loop mediated by protein phosphatase 1alpha mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer","volume":"45","author":"Liu","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"32","key":"10.1016\/j.jncc.2025.05.003_bib0129","doi-asserted-by":"crossref","first-page":"33743","DOI":"10.18632\/oncotarget.5608","article-title":"AR-v7 protein expression is regulated by protein kinase and phosphatase","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41417-024-00753-z","article-title":"Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT","volume":"31","author":"Kuo","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0131","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/nar\/gkq861","article-title":"Regulation of the androgen receptor by SET9-mediated methylation","volume":"39","author":"Gaughan","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0132","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/me.2010-0482","article-title":"Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase","volume":"25","author":"Ko","year":"2011","journal-title":"Mol Endocrinol"},{"issue":"33","key":"10.1016\/j.jncc.2025.05.003_bib0133","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220472120","article-title":"SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1","volume":"120","author":"Wang","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jncc.2025.05.003_bib0134","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biocel.2014.06.013","article-title":"Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells","volume":"54","author":"Krause","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"30","key":"10.1016\/j.jncc.2025.05.003_bib0135","doi-asserted-by":"crossref","first-page":"29782","DOI":"10.18632\/oncotarget.4927","article-title":"FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer","volume":"6","author":"Jones","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0136","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/onc.2017.385","article-title":"Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer","volume":"37","author":"Han","year":"2018","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0137","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","article-title":"Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer","volume":"52","author":"Gao","year":"2020","journal-title":"Nat Genet"},{"issue":"7057","key":"10.1016\/j.jncc.2025.05.003_bib0138","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0139","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.celrep.2014.11.008","article-title":"Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity","volume":"9","author":"Cai","year":"2014","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0140","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep"},{"issue":"19","key":"10.1016\/j.jncc.2025.05.003_bib0141","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkac861","article-title":"A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation","volume":"50","author":"Wang","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"27","key":"10.1016\/j.jncc.2025.05.003_bib0142","doi-asserted-by":"crossref","first-page":"20853","DOI":"10.1074\/jbc.M000660200","article-title":"p300 and p300\/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation","volume":"275","author":"Fu","year":"2000","journal-title":"J Biol Chem"},{"issue":"29","key":"10.1016\/j.jncc.2025.05.003_bib0143","doi-asserted-by":"crossref","first-page":"25904","DOI":"10.1074\/jbc.M203423200","article-title":"Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor","volume":"277","author":"Gaughan","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0144","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s42003-023-05709-x","article-title":"A carboxy-terminal ubiquitylation site regulates androgen receptor activity","volume":"7","author":"Arai","year":"2024","journal-title":"Commun Biol"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","article-title":"The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities","volume":"28","author":"Damgaard","year":"2021","journal-title":"Cell Death Differ"},{"issue":"15","key":"10.1016\/j.jncc.2025.05.003_bib0146","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1093\/emboj\/cdf406","article-title":"Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase","volume":"21","author":"Lin","year":"2002","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0147","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/emboj.2010.337","article-title":"The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin\/proteasome process","volume":"30","author":"Chymkowitch","year":"2011","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0148","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","article-title":"Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants","volume":"6","author":"An","year":"2014","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0149","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/onc.2012.561","article-title":"Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells","volume":"33","author":"Sarkar","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccr.2009.02.021","article-title":"Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination","volume":"15","author":"Xu","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0151","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/nar\/gkw1162","article-title":"Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity","volume":"45","author":"McClurg","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"10.1016\/j.jncc.2025.05.003_bib0152","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218229120","article-title":"TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer","volume":"120","author":"Singh","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0153","article-title":"MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer","volume":"4","author":"Khatiwada","year":"2024","journal-title":"Endocr Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0154","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12967-025-06115-z","article-title":"A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer","volume":"23","author":"Meng","year":"2025","journal-title":"J Transl Med"},{"issue":"5748","key":"10.1016\/j.jncc.2025.05.003_bib0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0156","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1593\/neo.07822","article-title":"Role of the TMPRSS2-ERG gene fusion in prostate cancer","volume":"10","author":"Tomlins","year":"2008","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0157","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccr.2010.03.018","article-title":"An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression","volume":"17","author":"Yu","year":"2010","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.jncc.2025.05.003_bib0158","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/s41388-019-0730-9","article-title":"TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells","volume":"38","author":"Zhou","year":"2019","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0159","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.3216","article-title":"ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss","volume":"19","author":"Chen","year":"2013","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jncc.2025.05.003_bib0160","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-18-0653","article-title":"TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer","volume":"24","author":"Blee","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0161","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1172\/JCI137967","article-title":"ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming","volume":"130","author":"Li","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.05.003_bib0162","doi-asserted-by":"crossref","unstructured":"Feng W., Ladewig E., Salsabeel N., et al. ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity. bioRxiv. 2024:2023.05.15.540839. https:\/\/doi.org\/10.1101\/2023.05.15.540839.","DOI":"10.1101\/2023.05.15.540839"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0163","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.05.003_bib0164","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ebiom.2017.04.006","article-title":"c-myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks","volume":"18","author":"Barfeld","year":"2017","journal-title":"EBioMedicine"},{"issue":"25","key":"10.1016\/j.jncc.2025.05.003_bib0165","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1038\/s41388-019-0768-8","article-title":"A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer","volume":"38","author":"Bai","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0166","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0167","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1038\/s41467-021-27077-y","article-title":"Androgen receptor and MYC equilibration centralizes on developmental super-enhancer","volume":"12","author":"Guo","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063563","article-title":"Androgen receptor promotes ligand-independent prostate cancer progression through c-myc upregulation","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0169","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113221","article-title":"MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer","volume":"42","author":"Crowell","year":"2023","journal-title":"Cell Rep"},{"issue":"6320","key":"10.1016\/j.jncc.2025.05.003_bib0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.jncc.2025.05.003_bib0171","doi-asserted-by":"crossref","first-page":"11897","DOI":"10.1158\/0008-5472.CAN-06-2497","article-title":"Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer","volume":"66","author":"Davis","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025187","article-title":"Repression of androgen receptor transcription through the E2F1\/DNMT1 axis","volume":"6","author":"Valdez","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jncc.2025.05.003_bib0173","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1172\/JCI44239","article-title":"The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression","volume":"120","author":"Sharma","year":"2010","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0174","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/0008-5472.CAN-21-1159","article-title":"Novel oncogenic transcription factor cooperation in RB-deficient cancer","volume":"82","author":"Mandigo","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0176","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.celrep.2016.09.064","article-title":"Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein","volume":"17","author":"Gao","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0177","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ymthe.2022.01.039","article-title":"Exploiting the tumor-suppressive activity of the androgen receptor by CDK4\/6 inhibition in castration-resistant prostate cancer","volume":"30","author":"Han","year":"2022","journal-title":"Mol Ther"},{"issue":"17","key":"10.1016\/j.jncc.2025.05.003_bib0178","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/0008-5472.CAN-22-2613","article-title":"Supraphysiological androgens promote the tumor suppressive activity of the androgen receptor through cMYC repression and recruitment of the DREAM complex","volume":"83","author":"Nyquist","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0179","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1158\/1535-7163.MCT-24-0716","article-title":"Heterogeneous responses to high-dose testosterone in castration-resistant prostate cancer tumors with mixed Rb-proficient and Rb-deficient cells","volume":"24","author":"Labaf","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0180","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","article-title":"ZNF397 Deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.05.003_bib0181","article-title":"CHD1, a multifaceted epigenetic remodeler in prostate cancer","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0182","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-12-1342","article-title":"CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer","volume":"73","author":"Burkhardt","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0183","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","article-title":"Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0184","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41698-024-00705-8","article-title":"Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression","volume":"8","author":"Diossy","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","article-title":"CHD1 Loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0186","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1541-7786.MCR-20-0913","article-title":"MAP3K7 Loss drives enhanced androgen signaling and independently confers risk of recurrence in prostate cancer with joint Loss of CHD1","volume":"19","author":"Jillson","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0187","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/2159-8290.CD-19-1352","article-title":"Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer","volume":"10","author":"Zhao","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.05.003_bib0188","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fendo.2012.00068","article-title":"FoxA1 is a key mediator of hormonal response in breast and prostate cancer","volume":"3","author":"Robinson","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0189","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrc3263","article-title":"Pioneer factors in hormone-dependent cancers","volume":"12","author":"Jozwik","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0190","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmb.2006.11.087","article-title":"Specific interactions of the wing domains of FOXA1 transcription factor with DNA","volume":"366","author":"Cirillo","year":"2007","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0191","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.molcel.2023.11.020","article-title":"FOXA1 forms biomolecular condensates that unpack condensed chromatin to function as a pioneer factor","volume":"84","author":"Ji","year":"2024","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0192","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.jncc.2025.05.003_bib0193","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat Genet"},{"issue":"7765","key":"10.1016\/j.jncc.2025.05.003_bib0194","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"issue":"7765","key":"10.1016\/j.jncc.2025.05.003_bib0195","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.jncc.2025.05.003_bib0196","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/emboj.2011.328","article-title":"Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer","volume":"30","author":"Sahu","year":"2011","journal-title":"EMBO J"},{"issue":"50","key":"10.1016\/j.jncc.2025.05.003_bib0197","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1038\/onc.2013.508","article-title":"Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype","volume":"33","author":"Robinson","year":"2014","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.jncc.2025.05.003_bib0198","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1016\/j.celrep.2019.08.039","article-title":"Meta-analysis of chromatin programming by steroid receptors","volume":"28","author":"Paakinaho","year":"2019","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.jncc.2025.05.003_bib0199","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cell.2016.02.067","article-title":"Steroid receptors reprogram FoxA1 occupancy through dynamic chromatin transitions","volume":"165","author":"Swinstead","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jncc.2025.05.003_bib0200","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/ncomms4972","article-title":"Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program","volume":"5","author":"Jin","year":"2014","journal-title":"Nat Commun"},{"issue":"7351","key":"10.1016\/j.jncc.2025.05.003_bib0201","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nature10006","article-title":"Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA","volume":"474","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0202","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/2159-8290.CD-21-0576","article-title":"Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence","volume":"12","author":"Linder","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0203","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41588-024-01893-6","article-title":"NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis","volume":"56","author":"Parolia","year":"2024","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jncc.2025.05.003_bib0204","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"7801","key":"10.1016\/j.jncc.2025.05.003_bib0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0206","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41422-019-0203-2","article-title":"Forkhead domain mutations in FOXA1 drive prostate cancer progression","volume":"29","author":"Gao","year":"2019","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0207","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41422-019-0204-1","article-title":"Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression","volume":"29","author":"Xu","year":"2019","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.05.003_bib0208","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/1078-0432.CCR-24-3471","article-title":"Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.05.003_bib0209","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41588-020-0591-8","article-title":"Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones","volume":"52","author":"Iwafuchi","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.05.003_bib0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s42003-018-0128-1","article-title":"Frequent mutation of the FOXA1 untranslated region in prostate cancer","volume":"1","author":"Annala","year":"2018","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0211","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1074\/jbc.M109.063149","article-title":"Stable chromatin binding prevents FoxA acetylation, preserving FoxA chromatin remodeling","volume":"285","author":"Kohler","year":"2010","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0212","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/me.2014-1035","article-title":"Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation","volume":"28","author":"Sutinen","year":"2014","journal-title":"Mol Endocrinol"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0213","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s43018-024-00820-2","article-title":"Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers","volume":"5","author":"Dong","year":"2024","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2025.05.003_bib0214","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0215","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","article-title":"LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.jncc.2025.05.003_bib0216","doi-asserted-by":"crossref","first-page":"eabe2261","DOI":"10.1126\/sciadv.abe2261","article-title":"Posttranslational regulation of FOXA1 by Polycomb and BUB3\/USP7 deubiquitin complex in prostate cancer","volume":"7","author":"Park","year":"2021","journal-title":"Sci Adv"},{"issue":"33","key":"10.1016\/j.jncc.2025.05.003_bib0217","doi-asserted-by":"crossref","first-page":"eadg7112","DOI":"10.1126\/sciadv.adg7112","article-title":"FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer","volume":"9","author":"Liu","year":"2023","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.jncc.2025.05.003_bib0218","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/jcb.25804","article-title":"Tyrosine phosphorylation of the pioneer transcription factor FoxA1 promotes activation of estrogen signaling","volume":"118","author":"Yamaguchi","year":"2017","journal-title":"J Cell Biochem"},{"issue":"13","key":"10.1016\/j.jncc.2025.05.003_bib0219","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111404","article-title":"FOXA1 regulates alternative splicing in prostate cancer","volume":"40","author":"Del Giudice","year":"2022","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0220","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/pros.24714","article-title":"FOXA1 regulates ribosomal RNA transcription in prostate cancer","volume":"84","author":"Jia","year":"2024","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.jncc.2025.05.003_bib0221","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/modpathol.2017.44","article-title":"FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate","volume":"30","author":"Park","year":"2017","journal-title":"Mod Pathol"},{"issue":"28","key":"10.1016\/j.jncc.2025.05.003_bib0222","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0223","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41467-021-22139-7","article-title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","volume":"12","author":"Baca","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jncc.2025.05.003_bib0224","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccr.2010.06.007","article-title":"HIF-1alpha partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis","volume":"18","author":"Eisinger-Mathason","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.05.003_bib0226","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.jncc.2025.05.003_bib0227","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147025","article-title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer","volume":"131","author":"He","year":"2021","journal-title":"J Clin Invest"},{"issue":"37","key":"10.1016\/j.jncc.2025.05.003_bib0228","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1038\/s41388-022-02423-6","article-title":"FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A","volume":"41","author":"Wang","year":"2022","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.jncc.2025.05.003_bib0229","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1093\/nar\/gkw498","article-title":"FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function","volume":"44","author":"Yang","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.jncc.2025.05.003_bib0230","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2016.11.028","article-title":"FOXA1 Directs H3K4 monomethylation at enhancers via recruitment of the methyltransferase MLL3","volume":"17","author":"Jozwik","year":"2016","journal-title":"Cell Rep"},{"issue":"23","key":"10.1016\/j.jncc.2025.05.003_bib0231","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jncc.2025.05.003_bib0232","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jncc.2025.05.003_bib0233","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115823","article-title":"Unveiling the molecular landscape of FOXA1 mutant prostate cancer: insights and prospects for targeted therapeutic strategies","volume":"24","author":"Hwang","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005425000602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005425000602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:12:22Z","timestamp":1776208342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005425000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":233,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2667005425000602"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.05.003","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}